5,045,460



FIGURE 1



Figure 2



Figure 2

D0805479 - 0805480

Patent Application Publication

Figure 4

US 6,048,960



Figure 5

A.



B.



Figure 6

09/940,760

Date Filed: 4/5/2005



Figure 7


HoxA7
L2
Absorbance units (OD450nm)
1.6
1.4
1.2
1
.8
.6
.4
.2
0
p<0.0001
n.s.
p<0.0001
MDS
PD
BSC
HV
MDS
PD
BSC
HV

Figure 8

A.
1. parental IOSE-29
2. IOSE-29.pcDNA-V-2
3. IOSE-29.pcDNA-B7-4
4. IOSE-29.pcDNA-B7-5
5. IOSE-29.pBK-V-2.1
6. IOSE-29.pBK-B7-1
7. IOSE-29.pBK-B7-5
8. IOSE-29.pIRES-V-1
9. IOSE-29.pIRES-B7-2
10. IOSE-29.pIRES-B7-3
HOXB7
β-actin
B.
C.

Figure 9


A
-poly(HEMA)
Absolute cell number per well
40000
30000
20000
10000
0
1 2 3 4
days in culture
B
-poly(HEMA)
Thymidine incorporation (cpm)
40000
30000
20000
10000
0
1 2 3 4
days in culture
C
+poly(HEMA)
Thymidine incorporation (cpm)
10000
7500
5000
2500
0
1 2 3 4
days in culture
transfected
IOSE-29
cell line
pcDNA-V-2
pcDNA-B7-4
pcDNA-B7-5
pBK-V-2.1
pBK-B7-1
pBK-B7-5
pIRES-V-1
pIRES-B7-2
pIRES-B7-3

Figure 10

Attorney Docket No. 21199-0003



Figure 11

ATGAGTTCATTGTATTATGCGAATGCTTTATTTTCTAAATATCCAGCCTCAAGTTCGGTTTTCGCTACCGGAGCCTTCCC
AGAACAAACTTCTTGTGCGTTTGCTTCCAACCCCCAGCGCCCGGGCTATGGAGCGGGTTCGGGCGCTTCCTTCGCCGCCT
CGATGCAGGGCTTGTACCCCGGCGGGGGGGGGCATGGCGGGCCAGAGCGCGGCCGGCGTCTACGCGGCCGGCTATGGGCTC
GAGCCGAGTTCCTTCAACATGCACTGCGCGCCCTTTGAGCAGAACCTCTCCGGGGTGTGTCCCGGCGACTCCGCCAAGGC
GGCGGGCGCCAAGGAGCAGAGGGACTCGGACTTGGCGGCCGAGAGTAACTTCCGGATCTACCCCTGGATGCGAAGCTCAG
GAACTGACCGCAAACGAGGCCGCCAGACCTACACCCGCTACCAGACCCTGGAGCTGGAGAAAGAATTTCACTACAATCGC
TACCTGACGCGGCGGCGGCGCATCGAGATCGCGCACACGCTCTGCCTCACGGAAAGACAGATCAAGATTTGGTTTCAGAA
CCGGCGCATGAAGTGGAAAAAGGAGAACAAGACCGCGGGCCCGGGGACCACCGGCCAAGACAGGGCTGAAGCAGAGGAGG
AAGAGGAAGAGTGAGGGATGGAGAAAGGGCAGAGGAAGAGACATGAGAAAGGGAGAGGAAGAGAAGCCCAGCTCTGGGAA
CTGAATCAGGAAACTCAAATCGAATAGGGAAGT

FIGURE 12